Julia Brotherton

List of Publications by Year
in descending order

171	7,291	66234	64668
papers	citations	42 h-index	79 g-index

173	173	173	5439
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet, The, 2019, 394, 497-509.	6.3	630
2	Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2015, 15, 565-580.	4.6	556
3	Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet, The, 2011, 377, 2085-2092.	6.3	434
4	The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health, The, 2019, 4, e19-e27.	4.7	268
5	Human Papillomavirus Vaccine Introduction â€“ The First Five Years. Vaccine, 2012, 30, F139-F148.	1.7	260
6	Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infectious Diseases, The, 2014, 14, 958-966.	4.6	243
7	Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Medicine, 2013, 11, 227.	2.3	232
8	Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. Journal of Infectious Diseases, 2012, 206, 1645-1651.	1.9	218
9	EUROGIN 2011 roadmap on prevention and treatment of HPVâ€related disease. International Journal of Cancer, 2012, 131, 1969-1982.	2.3	204
10	Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ, The, 2014, 348, g1458-g1458.	3.0	182
11	The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?. Eurosurveillance, 2018, 23, .	3.9	179
12	Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination. Journal of Infectious Diseases, 2018, 217, 1590-1600.	1.9	110
13	Human papillomavirus vaccine coverage among female Australian adolescents: success of the schoolâ€based approach. Medical Journal of Australia, 2013, 199, 614-617.	0.8	102
14	Safety of Human Papillomavirus Vaccines: A Review. Drug Safety, 2013, 36, 393-412.	1.4	100
15	Anaphylaxis following quadrivalent human papillomavirus vaccination. Cmaj, 2008, 179, 525-533.	0.9	98
16	Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sexual Health, 2011, 8, 171.	0.4	90
17	Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Safety, 2018, 41, 329-346.	1.4	86
18	A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. Journal of Infectious Diseases, 2018, 217, 208-212.	1.9	86

#	Article	IF	Citations
19	Womenâ€™s experience with home-based self-sampling for human papillomavirus testing. BMC Cancer, 2015, 15, 849.	1.1	81
20	Homeâ€based HPV selfâ€sampling improves participation by neverâ€screened and underâ€screened women: Results from a large randomized trial (iPap) in Australia. International Journal of Cancer, 2016, 139, 281-290.	2.3	80
21	Population Seroprevalence of Human Papillomavirus Types 6, 11, 16, and 18 in Men, Women, and Children in Australia. Clinical Infectious Diseases, 2008, 46, 1647-1655.	2.9	79
22	Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100177.	4.5	78
23	Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerging Infectious Diseases, 2016, 22, 1732-1740.	2.0	77
24	â€œIs cancer contagious?â€: Australian adolescent girls and their parents: Making the most of limited information about HPV and HPV vaccination. Vaccine, 2010, 28, 3398-3408.	1.7	74
25	Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2018, 47, 42-58.	1.4	72
26	Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. Preventive Medicine, 2011, 53, S29-S35.	1.6	69
27	Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial. PLoS Medicine, 2017, 14, e1002388.	3.9	67
28	Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Medicine, 2011, 9, 104.	2.3	66
29	HPV vaccine impact in Australian women: ready for an HPVâ€based screening program. Medical Journal of Australia, 2016, 204, 184-184.	0.8	65
30	Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 59-73.	4.5	62
31	Progress in HPV vaccination in lowâ€and lowerâ€middleâ€income countries. International Journal of Gynecology and Obstetrics, 2017, 138, 7-14.	1.0	61
32	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 2011, 29, 9112-9122.	1.7	58
33	Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: Independent estimates from a nationally representative mobile phone survey. Vaccine, 2014, 32, 592-597.	1.7	58
34	Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine, 2015, 33, 201-208.	1.7	51
35	Looking beyond human papillomavirus (HPV) genotype 16 and 18: Defining HPV genotype distribution in cervical cancers in Australia prior to vaccination. International Journal of Cancer, 2017, 141, 1576-1584.	2.3	51
36	HPV vaccination of immunocompromised hosts. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 35-38.	4.5	51

#	Article	IF	Citations
37	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011â€“2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	51
38	Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infectious Diseases, The, 2012, 12, 627-634.	4.6	50
39	The predicted impact of vaccination on human papillomavirus infections in Australia. International Journal of Cancer, 2008, 123, 1854-1863.	2.3	48
40	Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and Prevention. Vaccine, 2008, 26, M80-M88.	1.7	47
41	The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000â€2011). Cancer, 2016, 122, 1560-1569.	2.0	46
42	Self-Collection for Cervical Screening Programs: From Research to Reality. Cancers, 2020, 12, 1053.	1.7	46
43	â€œI just signedâ€¦ Factors influencing decision-making for school-based HPV vaccination of adolescent girls.. Health Psychology, 2010, 29, 618-625.	1.3	45
44	Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program. Vaccine, 2018, 36, 3221-3230.	1.7	43
45	Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes and Control, 2015, 26, 953-954.	0.8	42
46	Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sexual Health, 2010, 7, 310.	0.4	40
47	Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study. Vaccine, 2018, 36, 4311-4316.	1.7	40
48	Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Communicable Diseases Intelligence Quarterly Report, 2008, 32, 457-61.	0.6	39
49	Cervical screening rates for women vaccinated against human papillomavirus. Medical Journal of Australia, 2014, 201, 279-282.	0.8	38
50	Approaches to monitoring biological outcomes for HPV vaccination: Challenges of early adopter countries. Vaccine, 2011, 29, 878-885.	1.7	37
51	Age-specific HPV prevalence among 116,052 women in Australiaâ€™s renewed cervical screening program: A new tool for monitoring vaccine impact. Vaccine, 2019, 37, 412-416.	1.7	35
52	Primary Prevention of HPV through Vaccination: Update on the Current Global Status. Current Obstetrics and Gynecology Reports, 2016, 5, 210-224.	0.3	34
53	Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Research (Amsterdam, Netherlands), 2018, 6, 70-76.	4.5	32
54	Assessing HPV vaccine coverage in Australia by geography and socioeconomic status: are we protecting those most at risk?. Australian and New Zealand Journal of Public Health, 2014, 38, 419-423.	0.8	31

#	Article	IF	Citations
55	HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. Journal of Clinical Virology, 2014, 60, 250-256.	1.6	31
56	Current status of human papillomavirus vaccination. Current Opinion in Oncology, 2015, 27, 399-404.	1.1	28
57	The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation. Journal of Infectious Diseases, 2017, 216, 1205-1209.	1.9	28
58	HPV vaccine coverage is increasing in Australia. Medical Journal of Australia, 2017, 206, 262-262.	0.8	28
59	Rationale and design of the iPap trial: a randomized controlled trial of home-based HPV self-sampling for improving participation in cervical screening by never- and under-screened women in Australia. BMC Cancer, 2014, 14, 207.	1.1	24
60	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 268-277.	1.1	24
61	Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia. Cancer Epidemiology, 2012, 36, 298-302.	0.8	23
62	Impact of HPV vaccination: Achievements and future challenges. Papillomavirus Research (Amsterdam,) Tj ETQq0 0 0 rgBT /Overlock 10	4.5	23
63	Selfâ€collection cervical screening in the renewed National Cervical Screening Program: a qualitative study. Medical Journal of Australia, 2021, 215, 354-358.	0.8	23
64	Annual Immunisation Coverage Report 2017. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	23
65	Mobile phones are a viable option for surveying young Australian women: a comparison of two telephone survey methods. BMC Medical Research Methodology, 2011, 11, 159.	1.4	22
66	Implementation of the Australian HPV vaccination program for adult women: Qualitative key informant interviews. Vaccine, 2009, 27, 5505-5512.	1.7	21
67	National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program. Sexual Health, 2010, 7, 291.	0.4	21
68	Juvenile recurrent respiratory papillomatosis: 10â€year audit and Australian prevalence estimates. Laryngoscope, 2016, 126, 2827-2832.	1.1	21
69	<scp>HPV</scp> vaccination coverage and course completion rates for Indigenous Australian adolescents, 2015. Medical Journal of Australia, 2019, 211, 31-36.	0.8	21
70	Adverse events following HPV vaccination: 11Âyears of surveillance in Australia. Vaccine, 2020, 38, 6038-6046.	1.7	21
71	How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine, 2008, 26, 250-256.	1.7	20
72	Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer, 2013, 13, 296.	1.1	20

#	Article	IF	Citations
73	Human papillomavirus vaccination: Where are we now?. Journal of Paediatrics and Child Health, 2014, 50, 959-965.	0.4	20
74	HPV Vaccination: Current Global Status. Current Obstetrics and Gynecology Reports, 2015, 4, 220-233.	0.3	20
75	Monitoring the impact of HPV vaccine in malesâ€"Considerations and challenges. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 106-111.	4.5	20
76	Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25â€"69 years living in Australia. BMJ Open, 2018, 8, e016700.	0.8	20
77	School-based HPV vaccination positively impacts parentsâ€™ attitudes toward adolescent vaccination. Vaccine, 2021, 39, 4190-4198.	1.7	20
78	Immunisation coverage annual report, 2015. Communicable Diseases Intelligence (2018), 0, 43, .	0.3	20
79	Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study. Sexual Health, 2010, 7, 253.	0.4	19
80	Womenâ€™s views on human papillomavirus self-sampling: focus groups to assess acceptability, invitation letters and a test kit in the Australian setting. Sexual Health, 2015, 12, 279.	0.4	19
81	Eurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines. International Journal of Cancer, 2016, 139, 510-517.	2.3	19
82	IPVS statement on â€œTemporary HPV vaccine shortage: Implications globally to achieve equityâ€. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100195.	4.5	19
83	Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Communicable Diseases Intelligence Quarterly Report, 2011, 35, 197-201.	0.6	19
84	Implementation of Australiaâ€™s renewed cervical screening program: Preparedness of general practitioners and nurses. PLoS ONE, 2020, 15, e0228042.	1.1	18
85	HPV.edu study protocol: a cluster randomised controlled evaluation of education, decisional support and logistical strategies in school-based human papillomavirus (HPV) vaccination of adolescents. BMC Public Health, 2015, 15, 896.	1.2	17
86	Human papillomavirus vaccination update: Nonavalent vaccine and the two-dose schedule. , 2018, 47, 417-421.		17
87	Asking about human papillomavirus vaccination and the usefulness of registry validation: A study of young women recruited using Facebook. Vaccine, 2015, 33, 826-831.	1.7	16
88	A pilot study to compare dry cervical sample collection with standard practice of wet cervical samples for human papillomavirus testing. Journal of Clinical Virology, 2015, 69, 210-213.	1.6	16
89	Levels of anxiety and distress following receipt of positive screening tests in Australiaâ€™s HPV-based cervical screening programme: a cross-sectional survey. Sexually Transmitted Infections, 2020, 96, 166-172.	0.8	16
90	Annual Immunisation Coverage Report 2016. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	16

#	Article	IF	Citations
91	The incidence of genital warts in Australian women prior to the national vaccination program. Sexual Health, 2009, 6, 178.	0.4	15
92	Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact. Expert Review of Anti-Infective Therapy, 2011, 9, 627-639.	2.0	15
93	How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions. Vaccine, 2014, 32, 4082-4088.	1.7	15
94	Increased risk of cervical dysplasia in females with autoimmune conditionsâ€"Results from an Australia database linkage study. PLoS ONE, 2020, 15, e0234813.	1.1	15
95	Probability of Coincident Vaccination in the 24 or 48 Hours Preceding Sudden Infant Death Syndrome Death in Australia. Pediatrics, 2005, 115, e643-e646.	1.0	14
96	Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age? An important issue for postvaccination surveillance. Future Microbiology, 2012, 7, 193-199.	1.0	14
97	Measuring HPV vaccination coverage in Australia: comparing two alternative populationâ€based denominators. Australian and New Zealand Journal of Public Health, 2015, 39, 326-330.	0.8	14
98	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	0.6	14
99	Is the positive predictive value of highâ€grade cytology in predicting highâ€grade cervical disease falling due to HPV vaccination?. International Journal of Cancer, 2019, 144, 2964-2971.	2.3	14
100	Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children?. Journal of Paediatrics and Child Health, 2007, 43, 579-580.	0.4	13
101	Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions. Climacteric, 2019, 22, 596-602.	1.1	13
102	Time for a strategic research response to anal cancer. Sexual Health, 2012, 9, 628.	0.4	12
103	Effect of a School-Based Educational Intervention About the Human Papillomavirus Vaccine on Psychosocial Outcomes Among Adolescents. JAMA Network Open, 2021, 4, e2129057.	2.8	12
104	Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review. Vaccine, 2022, 40, A116-A123.	1.7	12
105	Estimating coverage of the National HPV Vaccination Program: where are we at?. Medical Journal of Australia, 2009, 191, 188-188.	0.8	11
106	Time to clinical investigation for Indigenous and nonâ€Indigenous Queensland women after a high grade abnormal Pap smear, 2000â€"2009. Medical Journal of Australia, 2017, 206, 73-77.	0.8	11
107	Health care provider perspectives on cervical screening for Aboriginal and Torres Strait Islander women: a qualitative study. Australian and New Zealand Journal of Public Health, 2021, 45, 150-157.	0.8	11
108	Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance. Clinical Infectious Diseases, 2017, 65, 827-832.	2.9	10

#	Article	IF	Citations
109	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. Preventive Medicine, 2021, 144, 106293.	1.6	10
110	Australian National Cervical Screening Program renewal: Attitudes and experiences of general practitioners, and obstetricians and gynaecologists. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2021, 61, 416-423.	0.4	10
111	Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sexually Transmitted Infections, 2014, 90, 532-537.	0.8	9
112	Human papillomavirus prevalence to age 60 years among Australian women prevaccination. Sexual Health, 2015, 12, 353.	0.4	9
113	Cervical Abnormalities Are More Common among Indigenous than Other Australian Women: A Retrospective Record-Linkage Study, 2000â€“2011. PLoS ONE, 2016, 11, e0150473.	1.1	9
114	Confirming cross-protection of bivalent HPV vaccine. Lancet Infectious Diseases, The, 2017, 17, 1227-1228.	4.6	9
115	HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination. Vaccine, 2020, 38, 6304-6311.	1.7	9
116	Australian Paediatric Surveillance Unit (APSU) Annual Surveillance Report 2019. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	9
117	Barriers to better threeâ€dose coverage with HPV vaccination in schoolâ€based programs. Australian and New Zealand Journal of Public Health, 2014, 38, 91-92.	0.8	8
118	Monitoring human papillomavirus prevalence among young Australian women undergoing routine chlamydia screening. Vaccine, 2020, 38, 1186-1193.	1.7	8
119	Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?. Tumour Virus Research, 2021, 11, 200216.	1.5	8
120	Getting the timing right: Womenâ€™s views on the best time to announce changes to cancer screening policy recommendations. Preventive Medicine Reports, 2020, 20, 101268.	0.8	8
121	Aboriginal and Torres Strait Islander women's views of cervical screening by selfâ€collection: a qualitative study. Australian and New Zealand Journal of Public Health, 2022, 46, 161-169.	0.8	8
122	HPV prophylactic vaccines: lessons learned from 10 years experience. Future Virology, 2015, 10, 999-1009.	0.9	7
123	IPVS Policy Statement addressing the burden of HPV disease for Indigenous peoples. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100191.	4.5	7
124	Opportunities to increase rates of human papillomavirus vaccination in the New South Wales school program through enhanced catch-up. Sexual Health, 2016, 13, 536.	0.4	6
125	Human papillomavirus prevalence and risk factors among Australian women 9â€“12Âyears after vaccine program introduction. Vaccine, 2021, 39, 4856-4863.	1.7	6
126	Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states. Vaccine, 2021, 39, 6117-6126.	1.7	6

#	Article	IF	Citations
127	Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females. Sexual Health, 2020, 17, 510.	0.4	6
128	Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia. Communicable Diseases Intelligence (2018), 2020, 44, .	0.3	6
129	The experience of under-screened and never-screened participants using clinician-supported self-collection cervical screening within the Australian National Cervical Screening Program. Women's Health, 2022, 18, 174550652210759.	0.7	6
130	Psychosocial impact of testing human papillomavirus positive in Australia's human papillomavirusâ€based cervical screening program: A crossâ€sectional survey. Psycho-Oncology, 2022, 31, 1110-1119.	1.0	6
131	Abnormal Pap tests after the HPV vaccine. Australian Family Physician, 2009, 38, 977-9.	0.5	6
132	Measuring school level attributable risk to support school-based HPV vaccination programs. BMC Public Health, 2022, 22, 822.	1.2	6
133	Ensuring a Successful Transition From Cytology to Human Papillomavirusâ€“Based Primary Cervical Cancer Screening in Canada by Investigating the Psychosocial Correlates of Womenâ€™s Intentions: Protocol for an Observational Study. JMIR Research Protocols, 2022, 11, e38917.	0.5	6
134	Offering HPV vaccination to women treated for high-grade cervical intra-epithelial neoplasia: What do you need to know?. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2014, 54, 393-394.	0.4	5
135	Could one dose of bivalent HPV vaccine prevent cervical cancer?. Lancet Oncology, The, 2015, 16, 739-740.	5.1	5
136	Estimating human papillomavirus vaccination coverage among young women in Victoria and reasons for non-vaccination. Sexual Health, 2016, 13, 190.	0.4	5
137	Assessment of attribution algorithms for resolving CIN3-related HPV genotype prevalence in mixed-genotype biopsy specimens using laser capture microdissection as the reference standard. Vaccine, 2020, 38, 6312-6319.	1.7	5
138	Study protocol: Yarning about HPV Vaccination: a qualitative study of factors influencing HPV vaccination among Aboriginal and Torres Strait Islander adolescents in Australia. BMJ Open, 2021, 11, e047890.	0.8	5
139	Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011â€“2015. Communicable Diseases Intelligence (2018), 2019, 43, .	0.3	5
140	Utility of reports and routine correspondence from the National HPV Vaccination Program Register. Medical Journal of Australia, 2013, 199, 463-463.	0.8	4
141	Reply to San Giorgi and Dikkers. Journal of Infectious Diseases, 2018, 217, 1504-1505.	1.9	4
142	Understanding the participation in cervical screening of Muslim women in Victoria, Australia from record-linkage data. Journal of Cancer Policy, 2019, 22, 100201.	0.6	4
143	IPVS policy statement. Equity in cervical cancer prevention: for all and not just for some. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100192.	4.5	4
144	School-Level Variation in Coverage of Co-Administered dTpa and HPV Dose 1 in Three Australian States. Vaccines, 2021, 9, 1202.	2.1	4

#	Article	IF	Citations
145	HPV vaccination coverage: slightly improved twoâ€dose schedule completion estimates and historical estimates lower on AIR than HPV Register. Australian and New Zealand Journal of Public Health, 2022, 46, 394-400.	0.8	4
146	HPV vaccines: so much learnt, so many more lessons to come. Lancet Oncology, The, 2016, 17, 8-9.	5.1	3
147	Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100190.	4.5	3
148	Understanding the proportion of cervical cancers attributable to <scp>HPV</scp>. Medical Journal of Australia, 2020, 212, 63.	0.8	3
149	Understanding the participation of breast screening among women born in predominantly Muslim countries living in Victoria, Australia from record-linkage data. PLoS ONE, 2020, 15, e0237341.	1.1	3
150	Interim estimates of male human papillomavirus vaccination coverage in the school-based program in Australia. Communicable Diseases Intelligence, 2015, 39, E197-200.	0.5	3
151	HPV self-sampling and follow-up over two rounds of cervical screening in Australia â€“ the iPap trial. Journal of Medical Screening, 2022, 29, 185-193.	1.1	3
152	Closing editorial: processes, opportunities and challenges after introduction of human papillomavirus vaccine. Sexual Health, 2010, 7, 397.	0.4	2
153	Two or three doses of human papillomavirus vaccine?. BMJ, The, 2015, 350, g7778-g7778.	3.0	2
154	Should Cervical Cancer Screening be Performed Before the Age of 25 Years?. Journal of Lower Genital Tract Disease, 2018, 22, 348-351.	0.9	2
155	More evidence suggesting that 1â€dose human papillomavirus vaccination may be effective. Cancer, 2020, 126, 1602-1604.	2.0	2
156	Vaccinations in patients with multiple sclerosis: review and recommendations. Medical Journal of Australia, 2021, 214, 350.	0.8	2
157	Impact of a Human Papillomavirus Vaccination Program within Organized Cervical Cancer Screening: Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 588-594.	1.1	2
158	Reasons for rejection of selfâ€collected samples for cervical screening. Medical Journal of Australia, 2022, 216, 214-214.	0.8	2
159	Advancements in the control of genital human papillomavirus infections and related diseases: highlighting Australia's role. Sexual Health, 2010, 7, 227.	0.4	1
160	HPV related surveillance activities in Australia. Vaccine, 2010, 28, 7453-7454.	1.7	1
161	P1-S1.53 Assessing HPV genotype prevalence in Australian women by Indigenous ethnicity pre-vaccination. Sexually Transmitted Infections, 2011, 87, A120-A121.	0.8	1
162	Genital HPV types in Australia. Lancet Infectious Diseases, The, 2012, 12, 102-103.	4.6	1

#	Article	IF	Citations
163	The value of data linkage depends on the quality of the data: incorporating Medicare data alters cervical screening analysis findings. Medical Journal of Australia, 2020, 212, 383-383.	0.8	1
164	Human papillomavirus vaccination. British Journal of Hospital Medicine (London, England: 2005), 2014, 75, C165-C168.	0.2	0
165	Authorsâ€™ reply: Safety of Human Papillomavirus Vaccines. Drug Safety, 2018, 41, 541-543.	1.4	0
166	Aboriginal women have a higher risk of cervical abnormalities at screening; South Australia, 1993â€“2016. Journal of Medical Screening, 2019, 26, 104-112.	1.1	0
167	Planning for human papillomavirus vaccines in Australia; report of a research group meeting. Communicable Diseases Intelligence Quarterly Report, 2004, 28, 249-54.	0.6	0
168	Title is missing!. , 2020, 15, e0228042.		0
169	Title is missing!. , 2020, 15, e0228042.		0
170	Title is missing!. , 2020, 15, e0228042.		0
171	Title is missing!. , 2020, 15, e0228042.		0